Today's Healthcare Pulse
Pharma Shifts Ad Spend to Spot TV Amid Heightened FDA Scrutiny
Pharmaceutical advertisers are redirecting dollars toward spot television placements as the FDA intensifies its oversight of drug marketing. The trend reflects a strategic move to capture audiences with shorter, targeted ads while navigating tighter regulatory expectations.
Also developing:
By the numbers: Apogee Therapeutics secures $1.3B royalty financing
Beam One-Ups Wave as Both Show Promise of Editing for AATD
Beam Therapeutics presented Phase 1/2 data for its DNA editor BEAM‑302, showing an 80% drop in mutated alpha‑1 antitrypsin (AAT) protein and lifting total AAT above the 11 µM protective threshold, with effects lasting 12 months. Wave Life Sciences reported its RNA editor WVE‑006 achieving up to a 59% single‑dose and 70% multi‑dose reduction in the mutant protein, but analysts deem the results modest compared with Beam. Both companies are pursuing accelerated FDA pathways, with Beam targeting a pivotal cohort in late 2026 and Wave expecting regulatory feedback mid‑2026. Pfizer will oversee global clinical and regulatory activities for Beam’s liver‑directed editor.
Mirum Pharma: A Rare Disease Growth Story to Watch
Mirum Pharmaceuticals reported Q1 2026 revenue of $521.3 million, a 43% year‑over‑year increase, driven primarily by its lead drug Livmarli, which posted $159.9 million in net product sales. The company lifted its full‑year revenue guidance to $660‑$680 million, representing a 26% YoY rise, while...
AbbVie’s New Immunology Standard-Bearer Skyrizi Kneels to UCB’s Bimzelx in Psoriatic Arthritis
UCB’s Bimzelx outperformed AbbVie’s Skyrizi in a Phase 3 head‑to‑head trial for psoriatic arthritis, achieving 49.1% ACR50 versus 38.4% for Skyrizi at week 16. While Bimzelx also showed numerically higher minimal disease activity (43% vs 39.9%), the difference missed statistical significance. Skyrizi...
Ketamine‑Buprenorphine Regimen Cuts Suicide Ideation by 76% in Trial
Researchers reported that a single ketamine infusion followed by four weeks of low‑dose buprenorphine lowered suicidal ideation by 76% in adults with major depressive disorder, far surpassing the 43% reduction seen with placebo. The double‑blind trial, published in the American...
University Hospitals Sussex 2026/27 Digital Workplan Highlights AI, Patient Communications, Cloud, Research
University Hospitals Sussex NHS Foundation Trust released its 2026/27 digital workplan, spotlighting a structured AI rollout, enhanced patient communications, and a green‑focused cloud migration strategy. An AI governance group and draft policy have been created, but the board notes limited...
Seventy-Ninth World Health Assembly Honours Global Champions Advancing Primary Health Care
The World Health Assembly honored six individuals and institutions for advancing primary health care and reducing health inequities. The laureates—representing Mali, Thailand, France, Singapore, Bangladesh and Egypt—received the Sasakawa, UAE, Kuwait, Dr Lee Jong‑wook, and Nelson Mandela awards. The 2026 ceremony...
Relay Therapeutics Posts 60% Response in Phase 2 Trial of Zovegalisib for Rare Vascular Anomalies
Relay Therapeutics said 60% of evaluable patients achieved a volumetric response in its Phase 2 ReInspire trial of zovegalisib for PIK3CA‑driven vascular anomalies. The data, presented at the ISSVA World Congress, outpace Novartis' prior 11% response and could position the...
NHS Rolls Out $1.14 Billion AI Framework to Transform UK Health Services
NHS Shared Business Services has launched a £900 million ($1.14 billion) eight‑year AI framework, inviting suppliers to bid across eight lots that span radiology, early‑detection, virtual‑robotic health and predictive analytics. The initiative aims to streamline procurement, boost clinical efficiency and accelerate AI‑driven...
ADAA’s Vision for Anxiety and Depression Care in 2026 and Beyond
The Anxiety & Depression Association of America (ADAA) outlined its 2025‑2028 strategic plan, emphasizing brand elevation, evidence‑based practice, and deeper member engagement. Recent milestones include the launch of the open‑access Journal of Mood and Anxiety Disorders and the rollout of...
Sensome Reports the INSPECT Study Results of Its In Situ Tumor Detection Technology for Lung Cancer
Sensome disclosed first‑in‑human data from its INSPECT study, evaluating a microsensor‑enabled smart stylet for bronchoscopic lung biopsies in 27 patients across Australia and France. The device records tissue electrical signatures immediately before sampling, allowing real‑time differentiation of healthy, necrotic and...
InMed‑Mentari All‑Stock Merger Sends Shares Up 160% and Triggers $290 Million Private Placement
InMed Pharmaceuticals announced an all‑stock merger with privately held Mentari Therapeutics, sending InMed shares up as much as 160% in a single session. The deal is accompanied by an oversubscribed $290 million private placement led by Fairmount and a slate of...
US Confirms First Ebola Case as Outbreak Swells; EPA Rolls Back PFAS Water Limits for 105 Million
The CDC verified that an American medical missionary contracted Ebola in the Democratic Republic of Congo, the first U.S. case in an outbreak that has exceeded 600 confirmed and suspected infections. At the same time, the EPA announced it will...
Hiltzik: Justice Department Attack on UCLA and Other Med Schools Shows It Has No Idea What Makes a Good Doctor
The Justice Department sent letters to UCLA and Yale medical schools accusing them of using race as a factor in admissions, claiming the practice violates a 2023 Supreme Court ruling on racial preferences. The article contends the DOJ’s analysis is...
Why Hospitals Keep Defaulting to Medicare Logic
The episode explores why hospitals default to Medicare reimbursement logic when navigating the shift from fee‑for‑service to value‑based care. Host and guest compare the transition to crossing a precarious bridge, noting that mixed payment models create confusion and hinder the...
Canagliflozin - Another Top Longevity Drug
A small, exploratory randomized trial tested dapagliflozin, an SGLT2 inhibitor, in early‑stage Alzheimer’s disease. The primary endpoint—magnetic resonance spectroscopy measurement of brain N‑acetylaspartate—showed no significant difference versus placebo. Nonetheless, the drug markedly increased systemic glucose disposal, confirming its expected metabolic...
Governance Serves as Foundation in Healthcare Transformation
Employers are overpaying roughly $4,000 per employee each year on health benefits, and the first remedy is robust governance. The article urges advisers to transition from a transactional "retailer" role to a fiduciary "guardian" by establishing a dedicated health‑plan committee....
Why ICD-10 Coding Accuracy Has Become Critical in Modern Healthcare Operations
ICD-10 coding accuracy has become a linchpin for modern healthcare operations, influencing everything from claim approvals to analytics and compliance. Hospitals now scrutinize documentation quality, denial patterns, and reimbursement performance, making coding a strategic function rather than a clerical task....
You Can Pry My Lamictal From My Cold, Dead Hands
A new policy championed by RFK Jr. seeks CMS reimbursement for clinicians’ time spent deprescribing antidepressants, addressing a long‑standing financial barrier. The STAT analysis notes that while the reimbursement model aligns with evidence, successful implementation also requires drug‑specific tapering protocols,...
BioMarin’s ENERGY 3 Trial of BMN 401 Meets One Co-Primary Endpoint
BioMarin Pharmaceutical announced that its Phase III ENERGY 3 trial of BMN 401 met one of two co‑primary endpoints, showing a statistically significant rise in plasma inorganic pyrophosphate (PPi) levels in children with ENPP1 deficiency through week 52. The trial failed to demonstrate any...
Why Healthcare Facilities Are Rethinking Disposable Glove Procurement
Healthcare providers are overhauling disposable glove procurement after the COVID‑era PPE shortage exposed supply‑chain fragility. Procurement teams now weigh vendor reliability, FDA and ASTM compliance, and ESG reporting alongside unit price. Biodegradable nitrile gloves that meet the same performance standards...
Medicaid Home-Based and Community-Based Services Long-Term Care Expenditures
The Balancing Incentive Program (BIP), created under the 2010 Affordable Care Act, offered states financial incentives to expand Medicaid home‑based and community‑based services (HCBS). Researchers compared 17 BIP‑participating states with a synthetic control of 17 non‑participating states using state‑level long‑term...
How AI Full Arch Implant Planning Is Changing Oral Surgery
AI-driven full‑arch implant planning is reshaping oral surgery by automating the traditionally labor‑intensive workflow. UK‑based 21D delivers an end‑to‑end system that handles 98% of planning from CBCT scan to surgical guide without a technician, claiming ~100 µm placement accuracy—about ten times...
Tuneable Peptide Biotech Parabilis Files IPO
Parabilis Medicines, the Cambridge‑based tuneable peptide biotech, filed a Nasdaq prospectus to raise roughly $100 million in an IPO under the PBLS ticker. The offering follows a $305 million private round and a multi‑billion‑dollar alliance with Regeneron, which contributed $50 million upfront and...
Eight Swedish Companies Spearheading the Country’s Biotech Scene in 2026
Sweden’s life‑science sector, now worth roughly $42 billion in turnover and employing over 52,000 people, is being propelled by eight standout biotech firms. Annexin Pharmaceuticals reported safety and early efficacy in a phase 2a ophthalmology trial, while Anocca raised $46 million to advance...
Lilly Snaps up Engage to Advance Non-Viral Genetic Medicines
Eli Lilly agreed to acquire Engage Biologics for up to $202 million in cash, adding the company’s non‑viral DNA delivery platform called Tethosome. The technology combines lipid‑nanoparticle shells with an mRNA‑encoded transport protein to move genetic payloads into cell nuclei without viral vectors....
Endologix Buys Clot Removal System From Surmodics
Endologix announced the acquisition of the Pounce peripheral thrombectomy system from Surmodics for an undisclosed price. Pounce, cleared by the FDA in 2020 and expanded with a larger version in 2024, uses dual nitinol baskets and a funnel to mechanically...
Solving the “Whac-A-Mole Dilemma”: A Smarter Way to Debias AI Vision Models
MIT, WPI, and Google researchers introduced Weighted Rotational DebiasING (WRING), a new post‑processing technique for vision‑language models. WRING rotates bias‑laden dimensions in the embedding space rather than projecting them out, preserving other learned relationships. In tests on CLIP‑style models, WRING...
Beyond Senolytics: Senoadaptive Drugs & Clinical Data on GPX4 Modulation (Dr. Marco Quarta, Rubedo)
In this episode, Dr. Marco Quarta, co‑founder and CSO of Rubedo Life Sciences, discusses the company’s breakthrough first‑in‑class GPX4‑modulating drug RLS1496, which has just reported preliminary Phase 1 basket‑trial data across multiple skin indications. He explains how Rubedo’s AI‑enabled single‑cell multi‑omics...
South Tyneside and Sunderland Highlights RPA for GP Referrals
South Tyneside and Sunderland NHS Foundation Trust reports that robotic process automation (RPA) has accelerated GP referral handling, with 77% of patients receiving planned treatment within 18 weeks—well above the 63.5% national average. Digital workers now make referrals available to...
Radiology Associates of North Texas Says It Will Waste over $51M on Costs Related to No Surprises Act
Radiology Associates of North Texas (RANT), the nation’s largest independent imaging group, says it will incur more than $51 million in administrative expenses tied to the No Surprises Act. The practice estimates it must file 68,000 arbitration batches, each costing $115...
Efficacy of Ustekinumab Combined with Partial Enteral Nutrition in Crohn’s Disease
A retrospective cohort of 124 Crohn’s disease patients showed that adding partial enteral nutrition (PEN) to ustekinumab (UST) therapy markedly improved long‑term mucosal healing. At week 54, endoscopic remission was achieved in 71.05% of the UST + PEN group versus 50.00% with...
West Hertfordshire Teaching Hospitals Shares Latest on AI Projects, UTC Integration, EPR Optimisation
West Hertfordshire Teaching Hospitals NHS Trust reported significant digital advances at its May board meeting, including the digitisation of ambulance handovers and the rollout of Cerner for its urgent treatment centre. The trust completed its HYDE ambient‑voice AI contract and...
Radiologists, Other Docs Quitting Clinical Practice Earlier and for Different Reasons than Before
New AMA research shows radiologists and other physicians are leaving clinical practice earlier than in past generations. The average age of departure is now 48 years, roughly nine years younger than the 57‑year average reported in 2008. “Hassle factor” and...
UCB Reports P-III (BE BOLD) Trial Data on Bimzelx in Active Psoriatic Arthritis
UCB disclosed Phase III BE BOLD trial results comparing its Bimzelx (bimekizumab) to AbbVie’s Skyrizi (risankizumab) in 553 adults with active psoriatic arthritis. The primary endpoint was met, with 49.1% of patients achieving an ACR50 response at week 16 versus 38.4%...
Dor Skuler, Intuition Robotics: Meet ElliQ
Intuition Robotics CEO Dor Skuler showcased ElliQ, an AI‑driven companion robot aimed at senior citizens. In a candid interview, Skuler highlighted ElliQ’s conversational abilities, health‑reminder functions, and its cultural references that resonate with older users. Medicaid programs in New York...
East of England Adult Critical Care Network Partners with Mela Solutions on Analytics Project
The East of England Adult Critical Care Network has teamed up with analytics firm Mela Solutions to launch a shared data platform. The system now contains over 220,000 admissions and 1.2 million assessment days, and early analysis shows a notable reduction...
Plantwatch: How Goat’s Rue Inspired Super Drug for Everything From Diabetes to Obesity
Goat’s rue (Galega officinalis) long served as a folk remedy for diabetes, its active molecule galegine lowering blood glucose but causing toxicity. Chemists later transformed galegine into metformin, a synthetic analogue that retains glucose‑lowering power without the harmful side effects....
Diphtheria Is Spreading in Australia and so Is Misinformation About It
Australia is experiencing a diphtheria outbreak that has reached several states and territories, with one confirmed death in the Northern Territory. The disease, once curbed by 1930s vaccination campaigns, is resurging in remote Aboriginal communities where immunisation rates have slipped....
J&J’s Duato Makes 358 Times His Median Employee; Vertex CEO Makes Just 80 Times
Johnson & Johnson chief Joaquin Duato earned $32.6 million in 2025, creating a 358‑to‑1 pay ratio with the median employee who earned $91,000—the widest gap among the ten pharma firms studied. Eli Lilly’s David Ricks followed with a $36.7 million package and a 293‑to‑1...
When Algorithms Decide Who Gets Health Care
Law professor Jennifer D. Oliva warns that AI‑powered coverage algorithms used by insurers to approve, deny, or limit care operate without FDA‑type safety testing. Her analysis shows that nearly one‑in‑five insured Americans experience claim denials, with 82% of physicians observing...
Financial Incentives, over Diagnosis, and Weak Oversight: Autism Claims Are Driving up Medicare Costs
A recent analysis reveals that Medicaid spending on applied behavior analysis (ABA) therapy for autism has exploded, rising 561% to over $2.2 billion across eight states. The surge is driven by massive overdiagnosis, with prevalence estimates inflating from 1 in 150...
Dr Louise Irvine: Setting up a Medical Advisory Network
Dr. Louise Irvine explains how she helped establish CanSG, a multidisciplinary clinical advisory network focused on sex‑related health issues, particularly the controversial use of puberty blockers and gender‑affirming treatments for youth. She outlines the group's origins in the UK, its...
Addus CEO: Moratorium Has Little To No Impact On Growth, Valuations
Addus HomeCare CEO Dirk Allison told investors that the CMS‑imposed moratorium on new home‑health Medicare enrollments will not hinder the company’s growth strategy. Because the freeze targets only home health and hospice, Addus’s personal care services segment remains untouched, allowing...
AI‑crafted Sensors Promise Earlier Cancer Detection
#AI-generated #Sensors open new paths for early cancer detection by Anne Trafton @MIT Learn more: https://t.co/udkbd5V4cP #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/6EWRhwCIGA
NHS Launches £900m AI Framework
The NHS Shared Business Services (NHS SBS) has issued a call for suppliers to join a new £900 million (≈ $1.15 billion) artificial‑intelligence framework that will run from May 2027 to May 2035. The eight‑year, eight‑lot open framework covers radiology and diagnostic imaging, early detection,...
Sinai Health Partners with Unity Health on Epic
Sinai Health announced it will adopt Unity Health’s Epic electronic patient record (EPR) system, extending a shared digital platform across two major Toronto academic hospitals. The move follows Ontario’s 2025 directive urging hospitals to consolidate into province‑wide EPR environments, accelerating...
Reduce Length of Stay by Eliminating Hidden Delays
Hospitals often track length of stay, bed turnover and patient throughput, but hidden coordination failures—delayed consults, inefficient transfers, fragmented handoffs—drive hidden inefficiencies. Hypercare’s upcoming webinar will dissect where these breakdowns occur across departments and care transitions. Speakers include Dr. Karim...
CareChain Helps Assess MSK Patients Earlier
The McGill University Health Centre (MUHC) is piloting CareChain, a digital platform from MultiCIM Technologies, to help physiotherapists conduct advanced musculoskeletal (MSK) assessments and triage patients who may need surgery. By standardising data collection and decision‑making, the tool aims to...
Leadless, Dual-Chamber Pacemakers for NB Patients
New Brunswick’s Horizon Heart Centre has become the first site in Canada to implant Abbott’s AVEIR DR dual‑chamber leadless pacemaker. The system uses two tiny, battery‑powered units—one in the right atrium and one in the right ventricle—that communicate wirelessly to mimic...
Spinal Neuromotor Rehabilitation Using a Portable Isokinetic Training Robot
Researchers at Beihang University and MIT unveiled a 0.96‑kg wearable robot that provides isokinetic resistance training for juveniles with spinal muscular atrophy type II. In a six‑week clinical trial with six participants, the device produced a 7° improvement in sit‑to‑stand knee...